P. aeruginosa is classified as a priority one pathogen by the World Health Organisation, and
new drugs are urgently needed, due to the emergence of multidrug-resistant (MDR) strains …

Polymyxins are well-established antibiotics that have recently regained significant interest
as a consequence of the increasing incidence of infections due to multidrug-resistant Gram …

Pseudomonas aeruginosa is an opportunistic pathogen affecting immunocompromised
patients. It is known as the leading cause of morbidity and mortality in cystic fibrosis (CF) …

Polymyxins are polycationic antimicrobial peptides that are currently the last-resort
antibiotics for the treatment of multidrug-resistant, Gram-negative bacterial infections. The …

Highlights•The antibiotic resistance crisis is jeopardizing feasibility of medical practices.•The
antibiotic resistance crisis is more serious with Gram-negative pathogens.•XDR phenotypes …

Polymyxins have recently been re-introduced into the therapeutic arsenal to combat
infections caused by multidrug-resistant Gram-negative bacteria. However, the emergence …

Polymyxin antibiotics are increasingly being used as last-line therapeutic options against a
number of multidrug resistant bacteria. These antibiotics show strong bactericidal activity …

While the misuse of antibiotics has clearly contributed to the emergence and proliferation of
resistant bacterial pathogens, with major health consequences, it remains less clear if the …

One of the most striking features of Pseudomonas aeruginosa is its outstanding capacity for
developing antimicrobial resistance to nearly all available antipseudomonal agents through …

Bacteria encounter a myriad of stresses in their natural environments, including, for
pathogens, their hosts. These stresses elicit a variety of specific and highly regulated …